Efficacy and Safety of TC011 in Relapsed or Refractory Follicular Lymphoma

Summary

This Phase II, multi-center, single-arm, open-label study evaluates the efficacy and safety of TC011, a CD19-targeted CAR-T cell therapy, in adult patients with relapsed or refractory follicular lymphoma (Grade 1, 2, or 3a). The primary endpoint is objective response rate (ORR) assessed by independent review using the Lugano 2014 classification.

Timeline

Start

2026-03-01

Primary completion

2028-05-31

Completion

2030-02-28

Drugs

Indications